Format

Send to

Choose Destination
Lancet Oncol. 2011 Sep;12(9):905-12. doi: 10.1016/S1470-2045(11)70056-0. Epub 2011 May 12.

Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

Author information

1
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. mrudek2@jhmi.edu

Abstract

Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.

PMID:
21570912
PMCID:
PMC3343721
DOI:
10.1016/S1470-2045(11)70056-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center